Press releases
- Evolus to Report Second Quarter Financial Results on July 31, 2024
- Evolus Announces Appointment of Albert G. White III to Board of Directors
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
- Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
- Evolus Reports First Quarter 2024 Results and Provides Business Update
More ▼
Key statistics
On Tuesday, Evolus Inc (EVL:BER) closed at 11.60, -17.73% below its 52-week high of 14.10, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.30 |
---|---|
High | 11.60 |
Low | 11.20 |
Bid | 11.30 |
Offer | 11.80 |
Previous close | 11.20 |
Average volume | 51.56 |
---|---|
Shares outstanding | 62.61m |
Free float | 48.91m |
P/E (TTM) | -- |
Market cap | 770.74m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 19:30 BST.
More ▼